“Alzheimer’s is open for business:” Controversial FDA approval could pave the way for future drugs

0
On Monday, a 17-year drought in the world of Alzheimer’s drugs ended with the FDA approval of Biogen’s Aduhlem (aducanumab). The controversy behind the FDA’s decision was considerable, but it doesn’t seem to be spooking drug developers who are now narrowing in on the degenerative brain disease.  In a nutshell, the approval of Aduhelm came after conflicting results from clinical…
« Previous post: | Next post: »